stoxline Quote Chart Rank Option Currency Glossary
  
Clovis Oncology, Inc. (CLVS)
0.0812  0 (0%)    12-20 16:00
Open: 0.0808
High: 0.0977
Volume: 24,212,259
  
Pre. Close: 0.0812
Low: 0.078
Market Cap: 0(M)
Technical analysis
2023-03-03 4:48:21 PM
Short term     
Mid term     
Targets 6-month :  0.15 1-year :  0.19
Resists First :  0.13 Second :  0.16
Pivot price 0.1
Supports First :  0.07 Second :  0.05
MAs MA(5) :  0.08 MA(20) :  0.1
MA(100) :  0.45 MA(250) :  1.11
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  10.5 D(3) :  9.2
RSI RSI(14): 31.6
52-week High :  3.25 Low :  0.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CLVS ] has closed above bottom band by 6.4%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.09 - 0.09 0.09 - 0.09
Low: 0.07 - 0.07 0.07 - 0.07
Close: 0.07 - 0.08 0.08 - 0.08
Company Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headline News

Thu, 30 May 2024
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review - Yahoo Lifestyle UK

Tue, 28 May 2024
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies UK

Tue, 28 May 2024
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? - Yahoo Movies UK

Fri, 24 May 2024
Clovis Up More Than 50% in 2017: What's Driving the Stock? - Yahoo Canada Shine On

Mon, 12 Dec 2022
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy - Markets Insider

Mon, 12 Dec 2022
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 145 (M)
Shares Float 143 (M)
Held by Insiders 1.4 (%)
Held by Institutions 25.8 (%)
Shares Short 28,490 (K)
Shares Short P.Month 30,770 (K)
Stock Financials
EPS -2.09
EPS Est Next Qtrly -1.15
EPS Est This Year -7.58
EPS Est Next Year -2.47
Book Value (p.s.) -2.9
Profit Margin -189.4 %
Operating Margin -155.2 %
Return on Assets (ttm) -30.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -19.2 %
Gross Profit (p.s.) 0.79
Sales Per Share 0.91
EBITDA (p.s.) -1.38
Qtrly Earnings Growth 0 %
Operating Cash Flow -176 (M)
Levered Free Cash Flow -128 (M)
Stock Valuations
PE Ratio -0.04
PEG Ratio 0
Price to Book value -0.03
Price to Sales 0.08
Price to Cash Flow -0.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android